Search

Your search keyword '"Souquet, P. J."' showing total 398 results
Start Over Author "Souquet, P. J."
398 results on '"Souquet, P. J."'

2. First-line nivolumab plus ipilimumab with two cycles of chemotherapy versus chemotherapy alone (four cycles) in advanced non-small-cell lung cancer: CheckMate 9LA 2-year update

Author

Reck, M., Ciuleanu, T.-E., Cobo, M., Schenker, M., Zurawski, B., Menezes, J., Richardet, E., Bennouna, J., Felip, E., Juan-Vidal, O., Alexandru, A., Sakai, H., Lingua, A., Reyes, F., Souquet, P.-J., De Marchi, P., Martin, C., Pérol, M., Scherpereel, A., Lu, S., Paz-Ares, L., Carbone, D.P., Memaj, A., Marimuthu, S., Zhang, X., Tran, P., and John, T.

Published
2021
Full Text
View/download PDF

22. Clinical Presentation, Diagnosis, and Bacterial Epidemiology of Peritoneal Tuberculosis in Two University Hospitals in France

Author

Cavalli, Zoé, Ader, Florence, Valour, Florent, Saison, Julien, Boussel, Loïc, Dumitrescu, Oana, Perpoint, Thomas, Chidiac, Christian, May, Thierry, Ferry, Tristan, Adelaïde, L., Ader, F., Biron, F., Boibieux, A., Bouaziz, A., Bouledrak, K., Braun, E., Broussolle, C., Carret, G., Catho, G., Charhon, N., Chidiac, C., Chumbi-Flores, W., Coppere, B., Couraud, S., Demontclos, M., Devouassoux, G., Dumitrescu, O., Ernesto, S., Ferry, T., Floret, D., Fredenucci, I., Freymond, N., Gardes, S., Gerbier-Colomban, S., Gillet, Y., Girard-Madoux, M. H., Goutelle, S., Grando, J., Grima, R., Hees, L., Hodille, E., Hot, A., Karsenty, J., Kiakouama-Maleka, L., Lina, G., Maury, J. M., Miailhes, P., Moreau, L., Nesme, P., Ninet, J., Perard, L., Perpoint, T., Perrot, E., Ranc, A. G., Rasigade, J. P., Reix, R., Renaud-Baron, A. S., Saison, J., Senechal, A., Sève, P., Souquet, P. J., van Thai, H., Tronc, F., Valour, F., Vanhems, P., and Lyon TB Study group

Published
2016
Full Text
View/download PDF

25. PTEN, ATM, IDH1 mutations and MAPK pathway activation as modulators of PFS and OS in patients treated by first line EGFR TKI, an ancillary study of the French Cooperative Thoracic Intergroup (IFCT) Biomarkers France project

Author

Blons, H., Oudart, J.-B., Merlio, J.-P., Debieuvre, D., De Fraipont, F., Audigier-Valette, C., Escande, F., Hominal, S., Bringuier, P-P, Fraboulet-Moreau, S., Ouafik, L., Moro-Sibilot, D., Lemoine, A., Langlais, A, Missy, P., Morin, F., Souquet, P.-J., Barlesi, F., Cadranel, J., Beau-Faller, M, Bringuier, P.‐P., Beau‐Faller, M., Institut de neurophysiopathologie (INP), Aix Marseille Université (AMU)-Centre National de la Recherche Scientifique (CNRS), Laboratoire de Transfert d'Oncologie Biologique [Hôpital Nord - APHM], Hôpital Nord [CHU - APHM]-Assistance Publique - Hôpitaux de Marseille (APHM)-Aix Marseille Université (AMU), Aix Marseille Université (AMU)-Assistance Publique - Hôpitaux de Marseille (APHM)- Hôpital Nord [CHU - APHM], Centre de Recherche en Cancérologie de Marseille (CRCM), Aix Marseille Université (AMU)-Institut Paoli-Calmettes, and Fédération nationale des Centres de lutte contre le Cancer (FNCLCC)-Fédération nationale des Centres de lutte contre le Cancer (FNCLCC)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)

Subjects
0301 basic medicine, Pulmonary and Respiratory Medicine, MAPK/ERK pathway, Oncology, Cancer Research, medicine.medical_specialty, Lung Neoplasms, IDH1, [SDV.CAN]Life Sciences [q-bio]/Cancer, Ataxia Telangiectasia Mutated Proteins, medicine.disease_cause, 03 medical and health sciences, 0302 clinical medicine, Non-small cell lung cancer, Carcinoma, Non-Small-Cell Lung, Internal medicine, Genotype, medicine, Humans, PTEN, In patient, Protein Kinase Inhibitors, Molecular profiles, biology, business.industry, PTEN Phosphohydrolase, Ancillary Study, Prognosis, medicine.disease, EGFR mutations, Isocitrate Dehydrogenase, 3. Good health, ErbB Receptors, 030104 developmental biology, 030220 oncology & carcinogenesis, Mutation, Next-generation sequencing, biology.protein, Adenocarcinoma, France, KRAS, business, Biomarkers
Abstract

Objectives Tumor mutation screening is standard of care for patients with stage IV NSCLC. Since a couple of years, widespread NGS approaches used in routine diagnostics to detect driver mutations such as EGFR, KRAS, BRAF or MET allows the identification of other alterations that could modulated the intensity or duration of response to targeted therapies. The prevalence of co-occurring alterations that could affect response or prognosis as not been largely analyzed in clinical settings and large cohorts of patients. Thanks to the IFCT program “Biomarkers France“, a collection of samples and data at a nation-wide level was available to test the impact of co-mutations on first line EGFR TKI in patients with EGFR mutated cancers. Materials and methods Targeted NGS was assessed on available (n = 208) samples using the Ion AmpliSeq™ Cancer Hotspot Panel v2 to screen for mutations in 50 different cancer genes. Results This study showed that PTEN inactivating mutations, ATM alterations, IDH1 mutations and complex EGFR mutations were predictors of short PFS in patients with a stage 4 lung adenocarcinoma receiving first line EGFR TKI and that PTEN, ATM, IDH1 and KRAS mutations as well as alterations in the MAPK pathway were related to shorter OS. Conclusion These findings may lead to new treatment options in patients with unfavorable genotypes to optimize first line responses.

Published
2021

30. Consolidation nivolumab and ipilimumab versus observation in limited-disease small-cell lung cancer after chemo-radiotherapy – results from the randomised phase II ETOP/IFCT 4-12 STIMULI trial

Author

Peters, S., primary, Pujol, J.-L., additional, Dafni, U., additional, Dómine, M., additional, Popat, S., additional, Reck, M., additional, Andrade, J., additional, Becker, A., additional, Moro-Sibilot, D., additional, Curioni-Fontecedro, A., additional, Molinier, O., additional, Nackaerts, K., additional, Insa Mollá, A., additional, Gervais, R., additional, López Vivanco, G., additional, Madelaine, J., additional, Mazieres, J., additional, Faehling, M., additional, Griesinger, F., additional, Majem, M., additional, González Larriba, J.L., additional, Provencio Pulla, M., additional, Vervita, K., additional, Roschitzki-Voser, H., additional, Ruepp, B., additional, Mitchell, P., additional, Stahel, R.A., additional, Le Pechoux, C., additional, De Ruysscher, D., additional, Stahel, R., additional, Hiltbrunner, A., additional, Pardo-Contreras, M., additional, Gasca-Ruchti, A., additional, Giacomelli, N., additional, Kammler, R., additional, Marti, N., additional, Pfister, R., additional, Piguet, A.C., additional, Roux, S., additional, Troesch, S., additional, Schneider, M., additional, Schweri, R., additional, Zigomo, I., additional, Tsourti, Z., additional, Zygoura, P., additional, Tsouprou, S., additional, Kassapian, M., additional, Dimopoulou, G., additional, Andriakopoulou, C., additional, Morin, F., additional, Amour, E., additional, Mariaule, G., additional, Archirel, N., additional, Fernandez, M., additional, Pereira, E., additional, Benito, L., additional, Lopez, K., additional, Hernández, A., additional, Chinchen, S., additional, Jurkovic, H., additional, Livingstone, A., additional, Mitchell, J., additional, Walker, M., additional, Ng, S., additional, Steer, C., additional, Briscoe, K., additional, Saqib, A., additional, Abdi, E., additional, Houghton, B., additional, O’Byrne, K., additional, Chittajallu, B.R., additional, Hughes, B.G., additional, Black, A., additional, Werner, H., additional, Zalcman, G., additional, Vaylet, F., additional, Merle, P., additional, Monnet, I., additional, Girard, N., additional, Souquet, P.-J., additional, Barlesi, F., additional, Debieuvre, D., additional, Senellart, H., additional, Poudenx, M., additional, Dixmier, A., additional, Pouessel, D., additional, Cadranel, J., additional, Lena, H., additional, Quoix, E., additional, Friard, S., additional, Audigier-Valette, C., additional, Pichon, E., additional, Kokowski, K., additional, Kirchen, H., additional, Tufman, A., additional, De-Colle, C., additional, de Langen, J., additional, Insa, A., additional, Massutí, B., additional, Pulla, M.P., additional, Aix, S.P., additional, Villanueva, N., additional, Vivanco, G.L., additional, Franks, K., additional, and Califano, R., additional

Published
2022
Full Text
View/download PDF

31. Corrigendum to ‘First-line nivolumab plus ipilimumab with 2 cycles of chemotherapy versus chemotherapy alone (4 cycles) in advanced non-small cell lung cancer: CheckMate 9LA 2-year update’: [ESMO Open Volume 6, Issue 5, October 2021, 100273]

Author

Reck, M., Ciuleanu, T.-E., Cobo, M., Schenker, M., Zurawski, B., Menezes, J., Richardet, E., Bennouna, J., Felip, E., Juan-Vidal, O., Alexandru, A., Sakai, H., Lingua, A., Reyes, F., Souquet, P.-J., De Marchi, P., Martin, C., Pérol, M., Scherpereel, A., Lu, S., Paz-Ares, L., Carbone, D.P., Memaj, A., Marimuthu, S., Zhang, X., Tran, P., and John, T.

Published
2021
Full Text
View/download PDF

34. Randomized phase II–III study of bevacizumab in combination with chemotherapy in previously untreated extensive small-cell lung cancer: results from the IFCT-0802 trial†

Author

Pujol, J.-L., Lavole, A., Quoix, E., Molinier, O., Souquet, P.-J., Barlesi, F., Le Caer, H., Moro-Sibilot, D., Fournel, P., Oster, J. P., Chatellain, P., Barre, P., Jeannin, G., Mourlanette, P., Derollez, M., Herman, D., Renault, A., Dayen, C., Lamy, P. J., Langlais, A., Morin, F., Zalcman, G., Westeel, V., Poudenx, M., Mazieres, J., Martinet, Y., Gury, J-P., Baize, N., Dumont, P., Vaylet, F., Foucher, P., Dauba, J., Tredaniel, J., Laize, H., Petit, L., Coëtmeur, D., Doubre, H., Pichon, E., Schneider, S., Goutorbe, F., Gervais, R., Zaegel, M., Dehette, S., Coudert, B., Duhamel, J-P., Dixmier, A., Thiberville, L., Deguiral, P., Monnot, H., Romand, P., Berard, H., and Raspaud, C.

Published
2015
Full Text
View/download PDF

41. First-line nivolumab plus ipilimumab with two cycles of chemotherapy versus chemotherapy alone (four cycles) in advanced non-small-cell lung cancer: CheckMate 9LA 2-year update.

Author

Reck, M, Ciuleanu, T-E, Cobo, M, Schenker, M, Zurawski, B, Menezes, J, Richardet, E, Bennouna, J, Felip, E, Juan-Vidal, O, Alexandru, A, Sakai, H, Lingua, A, Reyes, F, Souquet, P-J, De Marchi, P, Martin, C, Pérol, M, Scherpereel, A, Lu, S, Paz-Ares, L, Carbone, DP, Memaj, A, Marimuthu, S, Zhang, X, Tran, P, John, T, Reck, M, Ciuleanu, T-E, Cobo, M, Schenker, M, Zurawski, B, Menezes, J, Richardet, E, Bennouna, J, Felip, E, Juan-Vidal, O, Alexandru, A, Sakai, H, Lingua, A, Reyes, F, Souquet, P-J, De Marchi, P, Martin, C, Pérol, M, Scherpereel, A, Lu, S, Paz-Ares, L, Carbone, DP, Memaj, A, Marimuthu, S, Zhang, X, Tran, P, and John, T

Abstract

BACKGROUND: To further characterize survival benefit with first-line nivolumab plus ipilimumab with two cycles of chemotherapy versus chemotherapy alone, we report updated data from the phase III CheckMate 9LA trial with a 2-year minimum follow-up. PATIENTS AND METHODS: Adult patients were treatment naïve, with stage IV/recurrent non-small-cell lung cancer, no known sensitizing EGFR/ALK alterations, and an Eastern Cooperative Oncology Group performance status ≤1. Patients were randomized 1 : 1 to nivolumab 360 mg every 3 weeks plus ipilimumab 1 mg/kg every 6 weeks with two cycles of chemotherapy, or four cycles of chemotherapy. Updated efficacy and safety outcomes are reported, along with progression-free survival (PFS) after next line of treatment (PFS2), treatment-related adverse events (TRAEs) by treatment cycle, and efficacy outcomes in patients who discontinued all treatment components in the experimental arm due to TRAEs. RESULTS: With a median follow-up of 30.7 months, nivolumab plus ipilimumab with chemotherapy continued to prolong overall survival (OS) versus chemotherapy. Median OS was 15.8 versus 11.0 months [hazard ratio 0.72 (95% confidence interval 0.61-0.86)]; 2-year OS rate was 38% versus 26%. Two-year PFS rate was 20% versus 8%. ORR was 38% versus 25%, respectively; 34% versus 12% of all responses were ongoing at 2 years. Median PFS2 was 13.9 versus 8.7 months. Improved efficacy outcomes in the experimental versus control arm were observed across most subgroups, including by programmed death-ligand 1 and histology. No new safety signals were observed; onset of grade 3/4 TRAEs was mostly observed during the first two treatment cycles in the experimental arm. In patients who discontinued all components of nivolumab plus ipilimumab with chemotherapy treatment due to TRAEs (n = 61) median OS was 27.5 months; 56% of responders had an ongoing response ≥1 year after discontinuation. CONCLUSIONS: With a 2-year minimum follow-up, nivolumab plus ipilimumab wi

Published
2021

44. Capmatinib in patients with METex14-mutated or high-level MET-amplified advanced non-small- cell lung cancer (NSCLC): results from cohort 6 of the phase 2 GEOMETRY mono-1 study

Author

Wolf, J., Groen, H. J. M., Akerley, W., Souquet, P. -J., Laack, E., Han, J. -Y., Smit, E. F., Mansfield, A. S., Garon, E. B., Tan, D. S. W., Heist, R. S., Waldron-Lynch, M., Le Mouhaer, S., Nwana, N., Giovannini, M., Orlov, S., Wolf, J., Groen, H. J. M., Akerley, W., Souquet, P. -J., Laack, E., Han, J. -Y., Smit, E. F., Mansfield, A. S., Garon, E. B., Tan, D. S. W., Heist, R. S., Waldron-Lynch, M., Le Mouhaer, S., Nwana, N., Giovannini, M., and Orlov, S.

Published
2020

47. From randomized trials to the clinic: is it time to implement individual lung-cancer screening in clinical practice? A multidisciplinary statement from French experts on behalf of the french intergroup (IFCT) and the groupe dʼOncologie de langue française (GOLF)

Author

Couraud, S., Cortot, A. B., Greillier, L., Gounant, V., Mennecier, B., Girard, N., Besse, B., Brouchet, L., Castelnau, O., Frappé, P., Ferretti, G. R., Guittet, L., Khalil, A., Lefebure, P., Laurent, F., Liebart, S., Molinier, O., Quoix, E., Revel, M.-P., Stach, B., Souquet, P.-J., Thomas, P., Trédaniel, J., Lemarié, E., Zalcman, G., Barlési, F., and Milleron, B.

Published
2013
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results